Cell replacement as a route to treat cellular disease and injury is currently limited by the availability of suitable donor cell populations, but recent results with mouse embryonic stem cells suggest that isolated human pluripotent cells could provide a source of cells for transplantation and gene therapy.
Injury and disease states are often associated with loss or death of cells or with cellular dysfunction. In many such cases, cell replacement is a desirable option for restoration of tissue function. Bone marrow transfer to replace leukaemic blood cells is perhaps the best known example of this approach. Cell transplantation might also provide a useful way of delivering molecules for genetic therapy, either gene correction or gene addition. Stem cells derived from the early embryo might be expandable in culture to supply specific cell types for regenerative transplants. This possibility is considered here from both practical and scientific standpoints.
Successful cellular transplantation in general requires the use of stem cells. A molecular definition of a stem cell remains elusive. At the cellular level, however, a stem cell can be defined as a cell that has the capacity both to produce identical daughter cells -'self-renewal' -and to produce daughters that are fated to differentiate -'commitment'. The potential for self-renewal means that in principal a stem cell population can be maintained or expanded indefinitely (Figure 1 ).
Self-renewal is central to transplantation for two different reasons. The first is that it makes possible the long-term maintenance of grafts of renewing tissues. In tissues that undergo continuous turnover, such as the haematopoietic system, functionally mature cells survive for only finite periods. A red blood cell, for example, has an average life span of around 100 days. Effective transplantation therefore requires both initial reconstitution and ongoing replenishment of the entire tissue. This can only be achieved from a transferred stem cell population with the capacity for long-term self-renewal.
The second reason why self-renewal is so important is that it enables the large-scale production of cells for transplantation. In the case of 'cytostatic' tissues that do not undergo continuous turnover, such as the brain, transfer of stem cells should not be necessary for long-term graft maintenance. The mature neurons found in the adult brain are not readily isolated, however, and in any case they have little or no capacity to integrate into a new environment. Adaptable precursor cells can be obtained from foetal tissue, but this supply is limiting. The isolation and ex vivo expansion of stem cells is likely to prove crucial, therefore, for production of immature cells that are competent for functional incorporation into the adult tissue.
Efforts to isolate, expand and genetically manipulate stem cells from adult tissues have to date met with only partial success. An alternative to the primary derivation of tissuespecific stem cells would be the development of an in vitro system in which lineage-restricted stem cells could be generated from a founder stem cell population of human pluripotent stem cells (HPCs). Pluripotent cells with the capacity to generate all foetal and adult cell types exist only in the early embryo and in a particular type of germ cell tumour, teratocarcinoma.
HPCs from teratocarcinomas have been established in culture, but their tumour origin makes them unsuitable for therapeutic exploitation. In mice, however, the isolation of teratocarcinoma stem cells was followed by the derivation of non-transformed pluripotent stem cells directly from embryos [1] . These embryonic stem (ES) cells are genetically and phenotypically stable if cultured appropriately, and can be expanded indefinitely. They can be induced to differentiate in vitro into multiple lineages, including haematopoietic, myogenic, cardiac and neural cell types. Alternative stem cell fates.
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If undifferentiated ES cells are transplanted back into a mouse embryo they will contribute extensively to the developing foetus. The resulting chimaeric mice contain ES-cellderived functionally differentiated cell types in all tissues. This paradigm can be extended to transplantation into adults following in vitro differentiation. Haematopoietic, cardiac and neuronal derivatives of ES cells have recently been transferred directly into adult mice with evidence of functional engraftment [2] [3] [4] .
The isolation of HPCs analogous to mouse ES cells would thus create the possibility of generating human cells for transplantation. To make such a strategy possible, there are a number of key features that the HPCs should exhibit. Firstly, they should be pluripotent so that any desired cell type can be produced in vitro or in vivo. Secondly, they should be immortal, so that, unlike primary cells, they undergo unlimited expansion. Thirdly, they should be phenotypically stable, expressing no immortalising or transforming genes so as to minimise the risk of deregulated differentiation and tumour development. And fourthly, they should be genetically tractable so as to facilitate precise genome modifications, such as the introduction of therapeutic genes or engineering of immunocompatibility.
So what are the prospects of isolating such cells? Until fairly recently, proven ES cells had only been demonstrated in rodents. In a very significant development, however, Thomson and colleagues [5] have succeeded in establishing several pluripotent cell lines from embryos of both marmosets and rhesus macaques. Taken in conjunction with the occurrence in humans of teratocarcinomas containing pluripotent stem cells, the evidence suggests that the biological framework may be permissive for the isolation of HPCs. That this has not been achieved to date is in part due to the legislative and logistical issues involved in research with human embryonic material.
The conventional route to isolation of mouse ES cells is the culture of pre-implantation blastocysts, which contain a pluripotential stem cell population, the epiblast. In many countries, research using pre-implantation stages of human development is either not permitted or, as in the United States, is legal but may not be supported by government funds. In other countries, such as the United Kingdom, legislation allows for certain types of research under statutory guidelines. Eggs may be donated for research by couples receiving infertility treatment, or couples who have completed such treatment and have eggs remaining in frozen storage. However, a high proportion of the eggs tend to be abnormal and fail to develop to the blastocyst stage. The overall availability of human blastocysts is thus a limiting factor.
An alternative route is to attempt to derive HPCs at later stages using aborted foetal tissue. In the mouse, pluripotent cells with all the essential features of ES cells can be established by culturing primordial germ cells from the developing foetus [6] . The mechanism by which germ cells convert to ES cells is obscure, but recent work in pigs [7] indicates that this phenomenon may be reproduced in different mammals. Preliminary studies in humans suggest that pluripotent cells may be isolated by this route, although these cells have yet to be characterised in detail [8] .
Progress in establishing HPCs is also limited by our ignorance of the molecular basis of the pluripotent phenotype. The 'POU' domain transcription factor Oct-4 seems to be an essential hallmark of a pluripotent stem cell [9] , but the mechanisms that regulate Oct-4 expression are not known. The continuous propagation of mouse ES cells can be sustained by leukaemia inhibitory factor (LIF) or related cytokines that activate a second transcription factor, STAT3 [10] . With the exception of embryos from strain 129 mice, however, provision of LIF alone does not appear sufficient for the initial generation of ES cells from either epiblast or germ cells. This may be because additional signals are required [6, 11] , and/or because signals derived from differentiated cell types may induce differentiation or apoptosis of the stem cells [12] . This is an area in need of systematic research if we are to develop rational and robust methods for isolating HPCs.
A second area in which our present knowledge is inadequate is in the generation of pure populations of defined cell types. Using current protocols, the differentiation of ES cells is heterogeneous and disorganised, producing a mixture of cell types. Mixed cell populations are not suitable for transplantation, because they can provoke inappropriate host responses and may impede access of cells of interest to the host microenvironment. Furthermore, if undifferentiated HPCs persist, they may initiate teratoma development. The characterisation of inductive pathways that mediate lineage and cell-type-specific differentiation in the mammalian embryo holds the key to progress. This may be complemented by techniques for purifying specific cell types, for example by applying a genetic selection for expression of a marker gene [4, 13] .
Non-identity with the recipient would be a problem for transplantation using HPCs from embryonic sources. Immunosuppression would be required to avoid allogeneic rejection. It may prove possible to reduce this problem by genetic manipulation of histocompatibility loci. A preferred solution, however, would be to derive HPCs directly from the patient. Following the demonstration that nuclei of adult somatic cells can be reprogrammed to allow cloning -as in the production of the cloned sheep 'Dolly' -it is realistic to conceive of generating material for HPC derivation by nuclear transfer. Indeed in the future it may become routine for HPCs to be derived from individuals early in life and stored frozen for later use in regenerative and repair therapies (Figure 2 ).
Finally, ethical concerns have been expressed about efforts to establish HPCs. Such concerns derive from the requirement to use human embryonic material, as discussed above, and from the formal possibility that HPCs could be exploited for human germline modification. With regard to the latter concern, there are already various methods available by which the human germline could in theory be manipulated, and the advent of HPCs would not seem to present any significant new issues. The potential for transforming clinical practice should therefore outweigh hypothetical scenarios of abuse.
